0001104659-26-060678
SEC filingQ1 losses narrowed with operating income improving 9.5% to -$5.8M and net loss 14.4% to -$5.7M, reflecting cost discipline, while cash burn eased to -$4.8M. However, liquidity may not sustain operations beyond Q2 2027 without additional capital, as management plans cost measures and financing.
Cellectar Biosciences reported narrowing losses for Q1 FY2026, with operating income at -$5.8 million, a 9.5% improvement from -$6.4 million in the prior year quarter. This reflects disciplined cost management as the company advances its phospholipid drug conjugate (PDC) platform, which enables targeted oncologic payload delivery to all tumor cell types. The PDC technology's versatility supports ongoing clinical efforts in difficult-to-treat cancers like Waldenstrom macroglobulinemia (WM) and multiple myeloma (MM), where expansion cohorts target triple-class refractory patients.
Cash flow from operations improved markedly to -$4.8 million from -$9.4 million, signaling better working capital efficiency despite minimal capital expenditures of $3,378. This moderation in burn rate provides some breathing room, but liquidity remains precarious. Management notes the company may be unable to fund operations under normal course beyond Q2 2027 without further action. To mitigate this, leadership plans temporary cost-saving measures as needed and aims to secure additional capital through equity/debt sales or strategic transactions. While management believes these plans will succeed, no assurances are provided for effective implementation over the next twelve months.